Karivax is a Self-Assembling Nano Particle (SAPN) Platform based startup founded in 2024 in the city of San Diego by founder and inventor Dr. Eduardo Olmedillas (CSO), along with Co-founders Kanav Aggarwal (CEO) and Dr. Letitia Leung (COO).
SAPN platform can be used to develop
Immunotherapies (Auto-immune Disease, Cancer)
Vaccines (Coronavirus, Lassa, Influenza)
Drug delivery
Karivax utilizes innovative self-assembling protein nanoparticle technology to solve critical challenges in vaccine efficacy and delivery. Our approach enhances immune response precision, offers targeted cancer therapies, and improves delivery mechanisms, addressing the pressing need for more effective, versatile, and accessible immunotherapies and treatments in global healthcare.
About Us
Long Shelf Stable
Technology
High Temperature Stability and no cold chain storage required
Any Antigen
Illicit strong immune response through surface antigens. These antigen can be easily produced in bacteria. Can be customized with ease.
High Precision
With specific antigens, these nanoparticle targets with precision.
Affordable
With ease of production, manufacturing is inexpensive.